APOL1 Kidney Disease Risk Variants: An Evolving Landscape

Seminars in Nephrology

Volumn 35, Issue 3, 2015, Pages 222-236

  Dummer, Patrick D ^a   Limou, Sophie ^b   Rosenberg, Avi Z ^a,c   Heymann, Jurgen ^a   Nelson, George ^b   Winkler, Cheryl A ^b   Kopp, Jeffrey B ^a  

^a NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

APOL1; Chronic kidney disease; Focal segmental glomerulosclerosis; Health disparities; Innate immunity

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN L1; UNCLASSIFIED DRUG; APOL1 PROTEIN, HUMAN; HIGH DENSITY LIPOPROTEIN;

ALLELE; APOL1 GENE; APOPTOSIS; CELL BODY; CHANNEL GATING; CHRONIC KIDNEY DISEASE; CYTOTOXICITY; DIABETIC NEPHROPATHY; END STAGE RENAL DISEASE; FOCAL GLOMERULOSCLEROSIS; GENE; GENE EXPRESSION; GENE FUNCTION; GENETIC VARIABILITY; HEALTH DISPARITY; HIV ASSOCIATED NEPHROPATHY; HUMAN; IN VITRO STUDY; INNATE IMMUNITY; KIDNEY DISEASE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYSOSOME; MICROALBUMINURIA; MOLECULAR EVOLUTION; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SYSTEMS BIOLOGY; TRYPANOSOMA; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; RISK FACTOR;

APOLIPOPROTEINS; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; KIDNEY DISEASES; LIPOPROTEINS, HDL; RISK FACTORS;

EID: 84937966279     PISSN: 02709295     EISSN: 15584488     Source Type: Journal    
DOI: 10.1016/j.semnephrol.2015.04.008     Document Type: Review

References (110)

1. United States Renal Data System. Annual data report: epidemiology of kidney disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. 2014.
2. Kiberd B.A. Cumulative risk for developing end-stage renal disease in the US population. J Am Soc Nephrol 2002, 13:1635-1644.
3. Genovese G., Friedman D.J., Ross M.D., Lecordier L., Uzureau P., et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. Science 2010, 329:841-845.
4. Kopp J.B., Nelson G.W., Sampath K., Johnson R.C., Genovese G., et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011, 22:2129-2137.
5. Thomson R., Genovese G., Canon C., Kovacsics D., Higgins M.K., et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci U S A 2014, 111:E2130-E2139.
6. Limou S., Nelson G.W., Kopp J.B., Winkler C.A. APOL1 Kidney Risk Alleles: Population genetics and disease associations. Adv Chronic Kidney Dis 2014, 21:426-433.
7. Smith E.E., Malik H.S. The apolipoprotein L family of programmed cell death and immunity genes rapidly evolved in primates at discrete sites of host-pathogen interactions. Genome Res 2009, 19:850-858.
8. Page N.M., Butlin D.J., Lomthaisong K., Lowry P.J. The human apolipoprotein L gene cluster: identification, classification, and sites of distribution. Genomics 2001, 74:71-78.
9. Johnstone D.B., Shegokar V., Nihalani D., Rathore Y.S., Mallik L., et al. APOL1 null alleles from a rural village in India do not correlate with glomerulosclerosis. PLoS One 2012, 7:e51546.
10. Wan G., Zhaorigetu S., Liu Z., Kaini R., Jiang Z., et al. Apolipoprotein L1, a novel Bcl-2 homology domain 3-only lipid-binding protein, induces autophagic cell death. J Biol Chem 2008, 283:21540-21549.
11. Liu Z., Lu H., Jiang Z., Pastuszyn A., Hu C.A. Apolipoprotein l6, a novel proapoptotic Bcl-2 homology 3-only protein, induces mitochondria-mediated apoptosis in cancer cells. Mol Cancer Res 2005, 3:21-31.
12. Zhaorigetu S., Yang Z., Toma I., McCaffrey T.A., Hu C.A. Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells. J Biol Chem 2011, 286:27389-27398.
13. Zhaorigetu S., Wan G., Kaini R., Jiang Z., Hu C.A. ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy 2008, 4:1079-1082.
14. Ko W.Y., Rajan P., Gomez F., Scheinfeldt L., An P., et al. Identifying Darwinian selection acting on different human APOL1 variants among diverse African populations. Am J Hum Genet 2013, 93:54-66.
15. Nichols B., Jog P., Lee J.H., Blackler D., Wilmot M., et al. Innate immunity pathways regulate the nephropathy gene apolipoprotein L1. Kidney Int 2015, 87:332-342.
16. Vanhamme L., Paturiaux-Hanocq F., Poelvoorde P., Nolan D.P., Lins L., et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003, 422:83-87.
17. Perez-Morga D., Vanhollebeke B., Paturiaux-Hanocq F., Nolan D.P., Lins L., et al. Apolipoprotein L-I promotes trypanosome lysis by forming pores in lysosomal membranes. Science 2005, 309:469-472.
18. Pays E., Vanhollebeke B., Vanhamme L., Paturiaux-Hanocq F., Nolan D.P., et al. The trypanolytic factor of human serum. Nat Rev Microbiol 2006, 4:477-486.
19. Thomson R., Finkelstein A. Human trypanolytic factor APOL1 forms pH-gated cation-selective channels in planar lipid bilayers: relevance to trypanosome lysis. Proc Natl Acad Sci U S A 2015, 112:2894-2899.
20. Hamasaki M., Furuta N., Matsuda A., Nezu A., Yamamoto A., et al. Autophagosomes form at ER-mitochondria contact sites. Nature 2013, 495:389-393.
21. Galindo-Moreno J., Iurlaro R., El Mjiyad N., Diez-Perez J., Gabaldon T., et al. Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. Cell Death Dis 2014, 5:e1275.
22. Oda E., Ohki R., Murasawa H., Nemoto J., Shibue T., et al. Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science 2000, 288:1053-1058.
23. Capewell P., Veitch N.J., Turner C.M., Raper J., Berriman M., et al. Differences between Trypanosoma brucei gambiense groups 1 and 2 in their resistance to killing by trypanolytic factor 1. PLoS Negl Trop Dis 2011, 5:e1287.
24. Samanovic M., Molina-Portela M.P., Chessler A.D., Burleigh B.A., Raper J. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog 2009, 5:e1000276.
25. Taylor H.E., Khatua A.K., Popik W. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol 2014, 88:592-603.
26. Lan X., Jhaveri A., Cheng K., Wen H., Saleem M.A., et al. APOL1 risk variants enhance podocyte necrosis through compromising lysosomal membrane permeability. Am J Physiol Renal Physiol 2014, 307:F326-F336.
27. Vanhollebeke B., Pays E. The function of apolipoproteins L. Cell Mol Life Sci 2006, 63:1937-1944.
28. Hu C.A., Klopfer E.I., Ray P.E. Human apolipoprotein L1 (ApoL1) in cancer and chronic kidney disease. FEBS Lett 2012, 586:947-955.
29. Codogno P., Meijer A.J. Autophagy and signaling: their role in cell survival and cell death. Cell Death Differ 2005, 12(Suppl 2):1509-1518.
30. Fougeray S., Pallet N. Mechanisms and biological functions of autophagy in diseased and ageing kidneys. Nat Rev Nephrol 2015, 11:34-45.
31. Kroemer G., Jaattela M. Lysosomes and autophagy in cell death control. Nat Rev Cancer 2005, 5:886-897.
32. Wei M.C., Zong W.X., Cheng E.H., Lindsten T., Panoutsakopoulou V., et al. Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 2001, 292:727-730.
33. Lovell J.F., Billen L.P., Bindner S., Shamas-Din A., Fradin C., et al. Membrane binding by tBid initiates an ordered series of events culminating in membrane permeabilization by Bax. Cell 2008, 135:1074-1084.
34. Lomonosova E., Chinnadurai G. BH3-only proteins in apoptosis and beyond: an overview. Oncogene 2008, 27(Suppl 1):S2-S19.
35. Sinha S., Levine B. The autophagy effector Beclin 1: a novel BH3-only protein. Oncogene 2008, 27(Suppl 1):S137-S148.
36. Bellot G., Garcia-Medina R., Gounon P., Chiche J., Roux D., et al. Hypoxia-induced autophagy is mediated through hypoxia-inducible factor induction of BNIP3 and BNIP3L via their BH3 domains. Mol Cell Biol 2009, 29:2570-2581.
37. Kang R., Zeh H.J., Lotze M.T., Tang D. The Beclin 1 network regulates autophagy and apoptosis. Cell Death Differ 2011, 18:571-580.
38. Axe E.L., Walker S.A., Manifava M., Chandra P., Roderick H.L., et al. Autophagosome formation from membrane compartments enriched in phosphatidylinositol 3-phosphate and dynamically connected to the endoplasmic reticulum. J Cell Biol 2008, 182:685-701.
39. Zha J., Harada H., Osipov K., Jockel J., Waksman G., et al. BH3 domain of BAD is required for heterodimerization with BCL-XL and pro-apoptotic activity. J Biol Chem 1997, 272:24101-24104.
40. Puthalakath H., Villunger A., O'Reilly L.A., Beaumont J.G., Coultas L., et al. Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 2001, 293:1829-1832.
41. Fleischer A., Ayllon V., Dumoutier L., Renauld J.C., Rebollo A. Proapoptotic activity of ITM2B(s), a BH3-only protein induced upon IL-2-deprivation which interacts with Bcl-2. Oncogene 2002, 21:3181-3189.
42. Heneghan J., Alper S., Pollak M. BH3 domain-independent apolipoprotein L1 toxicity rescued by Bcl2 pro-survival proteins [abstract]. J Am Soc Nephrol 2014, 25:452A.
43. Lecordier L., Vanhollebeke B., Poelvoorde P., Tebabi P., Paturiaux-Hanocq F., et al. C-terminal mutants of apolipoprotein L-I efficiently kill both Trypanosoma brucei and Trypanosoma brucei rhodesiense. PLoS Pathog 2009, 5:e1000685.
44. Uzureau P., Uzureau S., Lecordier L., Fontaine F., Tebabi P., et al. Mechanism of Trypanosoma brucei gambiense resistance to human serum. Nature 2013, 501:430-434.
45. Molina-Portela Mdel P., Lugli E.B., Recio-Pinto E., Raper J. Trypanosome lytic factor, a subclass of high-density lipoprotein, forms cation-selective pores in membranes. Mol Biochem Parasitol 2005, 144:218-226.
46. Reeves-Daniel A.M., DePalma J.A., Bleyer A.J., Rocco M.V., Murea M., et al. The APOL1 gene and allograft survival after kidney transplantation. Am J Transplant 2011, 11:1025-1030.
47. Freedman B.I., Langefeld C.D., Lu L., Palmer N.D., Smith S.C., et al. APOL1 associations with nephropathy, atherosclerosis, and all-cause mortality in African Americans with type 2 diabetes. Kidney Int 2015, 87:176-181.
48. Lee B.T., Kumar V., Williams T.A., Abdi R., Bernhardy A., et al. The APOL1 genotype of African American kidney transplant recipients does not impact 5-year allograft survival. Am J Transplant 2012, 12:1924-1928.
49. Molina-Portela M.P., Samanovic M., Raper J. Distinct roles of apolipoprotein components within the trypanosome lytic factor complex revealed in a novel transgenic mouse model. J Exp Med 2008, 205:1721-1728.
50. Ma L., Shelness G.S., Snipes J.A., Murea M., Antinozzi P.A., et al. Localization of APOL1 protein and mRNA in the human kidney: nondiseased tissue, primary cells, and immortalized cell lines. J Am Soc Nephrol 2015, 26:339-348.
51. Uhlen M., Bjorling E., Agaton C., Szigyarto C.A., Amini B., et al. A human protein atlas for normal and cancer tissues based on antibody proteomics. Mol Cell Proteomics 2005, 4:1920-1932.
52. Uhlen M., Fagerberg L., Hallstrom B.M., Lindskog C., Oksvold P., et al. Proteomics. Tissue-based map of the human proteome. Science 2015, 347. 1260419.
53. Limou S, Dummer PD, Nelson GW, Kopp JB, Winkler CA. APOL1 toxin, innate immunity, and kidney injury. Kidney Int. 2015 Apr 8. [Epub ahead of print]. http://dx.doi.org/10.1038/ki.2015.109.
54. O'Toole JF MS, Thomas DB, Barisoni L, Bruggeman LA, Sedor JR. APOL1 Is an innate immunity effector that induces stress autophagy by interacting with the SNARE Protein,VAMP8 [Abstract]. ASN Annual Meeting. Atlanta, GA J Am Soc Nephrol. 2013;24:93A.
55. Rathore S.S., Ghosh N., Ouyang Y., Shen J. Topological arrangement of the intracellular membrane fusion machinery. Mol Biol Cell 2011, 22:2612-2619.
56. Davidson W.S., Silva R.A., Chantepie S., Lagor W.R., Chapman M.J., et al. Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol 2009, 29:870-876.
57. Raper J., Fung R., Ghiso J., Nussenzweig V., Tomlinson S. Characterization of a novel trypanosome lytic factor from human serum. Infect Immun 1999, 67:1910-1916.
58. Hajduk S.L., Moore D.R., Vasudevacharya J., Siqueira H., Torri A.F., et al. Lysis of Trypanosoma-brucei by a toxic subspecies of human high-density lipoprotein. J Biol Chem 1989, 264:5210-5217.
59. Pays E., Vanhollebeke B., Uzureau P., Lecordier L., Perez-Morga D. The molecular arms race between African trypanosomes and humans. Nat Rev Microbiol 2014, 12:575-584.
60. Capewell P., Cooper A., Clucas C., Weir W., Macleod A. A co-evolutionary arms race: trypanosomes shaping the human genome, humans shaping the trypanosome genome. Parasitology 2015, 142(Suppl 1):S108-S119.
61. Wheeler R.J. The trypanolytic factor-mechanism, impacts and applications. Trends Parasitol 2010, 26:457-464.
62. Litvinov D., Mahini H., Garelnabi M. Antioxidant and anti-inflammatory role of paraoxonase 1: implication in arteriosclerosis diseases. N Am J Med Sci 2012, 4:523-532.
63. Albert T.S., Duchateau P.N., Deeb S.S., Pullinger C.R., Cho M.H., et al. Apolipoprotein L-I is positively associated with hyperglycemia and plasma triglycerides in CAD patients with low HDL. J Lipid Res 2005, 46:469-474.
64. Bruggeman L.A., O'Toole J.F., Ross M.D., Madhavan S.M., Smurzynski M., et al. Plasma apolipoprotein L1 levels do not correlate with CKD. J Am Soc Nephrol 2014, 25:634-644.
65. Duchateau P.N., Movsesyan I., Yamashita S., Sakai N., Hirano K., et al. Plasma apolipoprotein L concentrations correlate with plasma triglycerides and cholesterol levels in normolipidemic, hyperlipidemic, and diabetic subjects. J Lipid Res 2000, 41:1231-1236.
66. Bentley A.R., Doumatey A.P., Chen G., Huang H., Zhou J., et al. Variation in APOL1 contributes to ancestry-level differences in HDLc-kidney function association. Int J Nephrol 2012, 2012:748984.
67. Freedman B.I., Langefeld C.D., Murea M., Ma L., Otvos J.D., et al. Apolipoprotein L1 nephropathy risk variants associate with HDL subfraction concentration in African Americans. Nephrol Dial Transplant 2011, 26:3805-3810.
68. Monajemi H., Fontijn R.D., Pannekoek H., Horrevoets A.J. The apolipoprotein L gene cluster has emerged recently in evolution and is expressed in human vascular tissue. Genomics 2002, 79:539-546.
69. Duchateau P.N., Pullinger C.R., Cho M.H., Eng C., Kane J.P. Apolipoprotein L gene family: tissue-specific expression, splicing, promoter regions; discovery of a new gene. J Lipid Res 2001, 42:620-630.
70. Liao W., Goh F.Y., Betts R.J., Kemeny D.M., Tam J., et al. A novel anti-apoptotic role for apolipoprotein L2 in IFN-gamma-induced cytotoxicity in human bronchial epithelial cells. J Cell Physiol 2011, 226:397-406.
71. Divers J., Nunez M., High K.P., Murea M., Rocco M.V., et al. JC polyoma virus interacts with APOL1 in African Americans with nondiabetic nephropathy. Kidney Int 2013, 84:1207-1213.
72. Mimmack M.L., Ryan M., Baba H., Navarro-Ruiz J., Iritani S., et al. Gene expression analysis in schizophrenia: reproducible up-regulation of several members of the apolipoprotein L family located in a high-susceptibility locus for schizophrenia on chromosome 22. Proc Natl Acad Sci U S A 2002, 99:4680-4685.
73. Hwang Y., Kim J., Shin J.Y., Kim J.I., Seo J.S., et al. Gene expression profiling by mRNA sequencing reveals increased expression of immune/inflammation-related genes in the hippocampus of individuals with schizophrenia. Transl Psychiatry 2013, 3:e321.
74. Tomita Y., Ikeda M., Mutoh H., Inada T., Iwata N., et al. Association study between Apolipoprotein L and schizophrenia by exhaustive and rule-based combination analysis for identification of multilocus interactions. J Biosci Bioeng 2007, 103:303-310.
75. Venkatasubramanian G., Arasappa R., Christopher R., Gangadhar B.N. Neuropharmacology of schizophrenia: is there a role for leptin?. Clin Chem Lab Med 2010, 48:895-896.
76. Carrera N., Arrojo M., Paz E., Ramos-Rios R., Agra S., et al. Testing the antagonistic pleiotropy model of schizophrenia susceptibility by analysis of DAOA, PPP1R1B, and APOL1 genes. Psychiatry Res 2010, 179:126-129.
77. McGhee K.A., Morris D.W., Schwaiger S., Nangle J.M., Donohoe G., et al. Investigation of the apolipoprotein-L (APOL) gene family and schizophrenia using a novel DNA pooling strategy for public database SNPs. Schizophr Res 2005, 76:231-238.
78. Takahashi S., Cui Y.H., Han Y.H., Fagerness J.A., Galloway B., et al. Association of SNPs and haplotypes in APOL1, 2 and 4 with schizophrenia. Schizophr Res 2008, 104:153-164.
79. Sutcliffe J.G., Thomas E.A. The neurobiology of apolipoproteins in psychiatric disorders. Mol Neurobiol 2002, 26:369-388.
80. Rastaldi M.P., Armelloni S., Berra S., Calvaresi N., Corbelli A., et al. Glomerular podocytes contain neuron-like functional synaptic vesicles. FASEB J 2006, 20:976-978.
81. Sistani L., Rodriguez P.Q., Hultenby K., Uhlen M., Betsholtz C., et al. Neuronal proteins are novel components of podocyte major processes and their expression in glomerular crescents supports their role in crescent formation. Kidney Int 2013, 83:63-71.
82. Kobayashi N. Mechanism of the process formation; podocytes vs. neurons. Microsc Res Tech 2002, 57:217-223.
83. Freedman B.I., Langefeld C.D. The new era of APOL1-associated glomerulosclerosis. Nephrol Dial Transplant 2012, 27:1288-1291.
84. Hoy WE, Hughson MD, Kopp JB, Mott SA, Bertram JF, et al. APOL1 risk alleles are associated with exaggerated age-related changes in glomerular number and volume in African American adults: an autopsy study. J Am Soc Nephrol. 2015 Jun 2. pii: ASN.2014080768 [Epub ahead of print].
85. Atta M.G., Estrella M.M., Kuperman M., Foy M.C., Fine D.M., et al. HIV-associated nephropathy patients with and without apolipoprotein L1 gene variants have similar clinical and pathological characteristics. Kidney Int 2012, 82:338-343.
86. Fine D.M., Wasser W.G., Estrella M.M., Atta M.G., Kuperman M., et al. APOL1 risk variants predict histopathology and progression to ESRD in HIV-related kidney disease. J Am Soc Nephrol 2012, 23:343-350.
87. Estrella M.M., Wyatt C.M., Pearce C.L., Li M., Shlipak M.G., et al. Host APOL1 genotype is independently associated with proteinuria in HIV infection. Kidney Int 2013, 84:834-840.
88. Kasembeli A.N., Duarte R., Ramsay M., Mosiane P., Dickens C., et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in black South Africans. J Am Soc Nephrol 2015, In press.
89. Papeta N., Kiryluk K., Patel A., Sterken R., Kacak N., et al. APOL1 variants increase risk for FSGS and HIVAN but not IgA nephropathy. J Am Soc Nephrol 2011, 22:1991-1996.
90. Kopp J.B., Winkler C.A., Zhao X., Radeva M.K., Gassman J.J., et al. Clinical features and histology of apolipoprotein L1-associated nephropathy in the FSGS Clinical Trial. J Am Soc Nephrol 2015, In press.
91. Ashley-Koch A.E., Okocha E.C., Garrett M.E., Soldano K., De Castro L.M., et al. MYH9 and APOL1 are both associated with sickle cell disease nephropathy. Br J Haematol 2011, 155:386-394.
92. Lipkowitz M.S., Freedman B.I., Langefeld C.D., Comeau M.E., Bowden D.W., et al. Apolipoprotein L1 gene variants associate with hypertension-attributed nephropathy and the rate of kidney function decline in African Americans. Kidney Int 2013, 83:114-120.
93. Freedman B.I., Langefeld C.D., Andringa K.K., Croker J.A., Williams A.H., et al. End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 2014, 66:390-396.
94. Larsen C.P., Beggs M.L., Saeed M., Walker P.D. Apolipoprotein L1 risk variants associate with systemic lupus erythematosus-associated collapsing glomerulopathy. J Am Soc Nephrol 2013, 24:722-725.
95. Friedman J.R., Dibenedetto J.R., West M., Rowland A.A., Voeltz G.K. Endoplasmic reticulum-endosome contact increases as endosomes traffic and mature. Mol Biol Cell 2013, 24:1030-1040.
96. Foster M.C., Coresh J., Fornage M., Astor B.C., Grams M., et al. APOL1 variants associate with increased risk of CKD among African Americans. J Am Soc Nephrol 2013, 24:1484-1491.
97. Ulasi II M., Tzur S., Wasser W.G., Shemer R., Kruzel E., et al. High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013, 123:123-128.
98. Kanji Z., Powe C.E., Wenger J.B., Huang C., Ankers E., et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 2011, 22:2091-2097.
99. Tzur S., Rosset S., Skorecki K., Wasser W.G. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 2012, 27:1498-1505.
100. Kofman T., Narjoz C., Raimbourg Q., Loriot M.A., Karras A., et al. Collapsing glomerulopathy associated lupus in a black female with homozygous APOL1 mutation. Lupus 2012, 21:1459-1462.
101. Larsen C.P., Beggs M.L., Walker P.D., Saeed M., Ambruzs J.M., et al. Histopathologic effect of APOL1 risk alleles in PLA2R-associated membranous glomerulopathy. Am J Kidney Dis 2014, 64:161-163.
102. Canaud G., Dejucq-Rainsford N., Avettand-Fenoel V., Viard J.P., Anglicheau D., et al. The kidney as a reservoir for HIV-1 after renal transplantation. J Am Soc Nephrol 2014, 25:407-419.
103. Palmer N.D., Ng M.C., Hicks P.J., Mudgal P., Langefeld C.D., et al. Evaluation of candidate nephropathy susceptibility genes in a genome-wide association study of African American diabetic kidney disease. PLoS One 2014, 9:e88273.
104. Ito K., Bick A.G., Flannick J., Friedman D.J., Genovese G., et al. Increased burden of cardiovascular disease in carriers of APOL1 genetic variants. Circ Res 2014, 114:845-850.
105. Langefeld C.D., Divers J., Pajewski N.M., Hawfield A.T., Reboussin D.M., et al. Apolipoprotein L1 gene variants associate with prevalent kidney but not prevalent cardiovascular disease in the Systolic Blood Pressure Intervention Trial. Kidney Int 2015, 87:169-175.
106. Parsa A., Kao W.H., Xie D., Astor B.C., Li M., et al. APOL1 risk variants, race, and progression of chronic kidney disease. N Engl J Med 2013, 369:2183-2196.
107. Friedman D.J., Kozlitina J., Genovese G., Jog P., Pollak M.R. Population-based risk assessment of APOL1 on renal disease. J Am Soc Nephrol 2011, 22:2098-2105.
108. Wheeler T.J., Clements J., Finn R.D. Skylign: a tool for creating informative, interactive logos representing sequence alignments and profile hidden Markov models. BMC Bioinformatics 2014, 15:7.
109. Finn R.D., Bateman A., Clements J., Coggill P., Eberhardt R.Y., et al. Pfam: the protein families database. Nucleic Acids Res 2014, 42:D222-D230.
110. Mitchell A., Chang H.Y., Daugherty L., Fraser M., Hunter S., et al. The InterPro protein families database: the classification resource after 15 years. Nucleic Acids Res 2015, 43:D213-D221.